The most frequent genetic alterations in patients with Ph‐like ALL are rearrangements of cytokine receptor like factor 2 (CRLF2),9 which are strongly associated with adverse clinical and treatment response factors and a higher risk of relapse with conventional therapy. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.